Genzyme, A Sanofi Company
Clinical trials sponsored by Genzyme, A Sanofi Company, explained in plain language.
-
Promising kidney drug trial for alport syndrome halted early
Disease control TerminatedThis study tested a weekly injection called lademirsen in 43 adults with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if the drug could slow the loss of kidney function and check for side effects. The trial was stopped early, but the results help…
Phase: PHASE2 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated May 17, 2026 06:50 UTC
-
Experimental drug for rare brain diseases shows promise but trial ends early
Disease control TerminatedThis study tested an oral drug called venglustat in adults and children with late-onset Tay-Sachs or Sandhoff disease, rare genetic disorders that damage the nervous system. The goal was to see if the drug could reduce harmful substances in the brain and slow disease progression.…
Phase: PHASE3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
MS drug trial for kids halted early: what we know
Disease control TerminatedThis study aimed to see if the drug alemtuzumab could help children aged 10 to 17 with relapsing-remitting multiple sclerosis (MS) whose disease was still active despite other treatments. Researchers planned to measure brain lesions and safety, but the study was stopped early aft…
Phase: PHASE3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated May 13, 2026 16:04 UTC